StockNews.AISignal intelligence
Company intelligence

IDXX

IDEXX Laboratories, Inc. · NASDAQ · Healthcare

Price$676.21-1.95% · −$13.44
Market cap53.28BEquity value
P / E47.5Trailing ratio
Volume614.31KLatest session
Market data

IDXX price chart

TradingView
Related signals
1 min delayed

Browse public IDXX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

IDXXNov 2, 2026+4.57% since signal

IDEXX surges on Q3 beat and higher FY26 guidance

IDEXX Laboratories posted a solid Q3 beat with $4.01 per share on $1.214 billion in revenue, topping estimates of $3.71 and $1.191 billion. The company also raised its FY26 guidance above expectations, prompting a roughly 20% stock jump to $661.77. This signals stronger growth visibility and could support further multiple expansion amid a broad market rally.

View signal analysis
IDXXAug 4, 2026-1.89% since signal

IDEXX Q2 Beat Drives Raised 2026 Guidance, Recurring Diagnostics Growth Sustains Upside

IDEXX posted a Q2 beat with EPS of $4.27 and revenue of $1.217B, lifting 2026 guidance above consensus. Growth was led by the Companion Animal Diagnostics stack and continued instrument placements, signaling durability in recurring revenue despite weaker wellness visits. The catalysts include Cancer Dx expansion and InVue Dx enhancements, supporting upside into 2H2026.

View signal analysis
Research

Company intelligence